Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer.
Harter P, du Bois A, Mahner S, Pfisterer J, Ortmann O, Marth C, Fink D, Hilpert F, Wagner U, Sehouli J. Harter P, et al. Among authors: hilpert f. Geburtshilfe Frauenheilkd. 2016 Feb;76(2):147-149. doi: 10.1055/s-0035-1568169. Geburtshilfe Frauenheilkd. 2016. PMID: 26941446 Free PMC article.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Clinical picture: nail changes secondary to docetaxel.
Wasner G, Hilpert F, Baron R, Pfisterer J. Wasner G, et al. Among authors: hilpert f. Lancet. 2001 Mar 24;357(9260):910. doi: 10.1016/s0140-6736(00)04210-0. Lancet. 2001. PMID: 11289346 No abstract available.
State-of-the-art first-line treatment of ovarian cancer.
Pfisterer J, Hilpert F, Du Bois A, Meier W, Wagner U. Pfisterer J, et al. Among authors: hilpert f. Onkologie. 2003 Oct;26(5):446-50. doi: 10.1159/000072977. Onkologie. 2003. PMID: 14605460 Review.
[Advances in the treatment of ovarian carcinoma].
Pfisterer J, du Bois A, Hilpert F, Wagner U, Meier W. Pfisterer J, et al. Among authors: hilpert f. Dtsch Med Wochenschr. 2004 Feb 20;129(8):379-84. doi: 10.1055/s-2004-819897. Dtsch Med Wochenschr. 2004. PMID: 14961446 Review. German. No abstract available.
Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group.
Pfisterer J, du Bois A, Wagner U, Quaas J, Blohmer JU, Wallwiener D, Hilpert F; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Pfisterer J, et al. Among authors: hilpert f. Gynecol Oncol. 2004 Mar;92(3):949-56. doi: 10.1016/j.ygyno.2003.12.004. Gynecol Oncol. 2004. PMID: 14984965 Clinical Trial.
Anti-idiotypic antibody abagovomab in advanced ovarian cancer.
Bauerschlag DO, Schem C, Baumann K, Harter P, Hilpert F, Wagner U, du Bois A, Pfisterer J. Bauerschlag DO, et al. Among authors: hilpert f. Future Oncol. 2008 Dec;4(6):769-73. doi: 10.2217/14796694.4.6.769. Future Oncol. 2008. PMID: 19086842 Review.
160 results